Kissei Pharmaceutical Co Ltd (JP:4547)
:4547
Want to see JP:4547 full AI Analyst Report?
4547 Stock Chart & Stats
¥4610.00
-¥35.00(-0.84%)
At close: 4:00 PM EST
¥4610.00
-¥35.00(-0.84%)
Day’s Range― - ―
52-Week Range¥3,500.00 - ¥5,040.00
Previous CloseN/A
Volume139.00K
Average Volume (3M)67.88K
Market Cap
¥153.38B
Enterprise Value¥133.44B
Total Cash (Recent Filing)¥48.75B
Total Debt (Recent Filing)¥1.77B
Price to Earnings (P/E)11.5
Beta0.45
Next Earnings
Aug 03, 2026EPS Estimate
55.99Next Dividend Ex-DateN/A
Dividend Yield2.48%
Share Statistics
EPS (TTM)289.63
Shares Outstanding46,541,985
10 Day Avg. Volume76,260
30 Day Avg. Volume67,883
Financial Highlights & Ratios
PEG Ratio0.67
Price to Book (P/B)0.84
Price to Sales (P/S)1.98
P/FCF Ratio-30.35
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
¥5,200.00Price Target Upside12.80% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
EPS Forecast (FY)285.87
Revenue Forecast (FY)¥97.22B
Bulls Say, Bears Say
Bulls Say
Balance Sheet StrengthVery low leverage and stable equity/assets provide durable financial flexibility. This allows Kissei to fund R&D, manage development timelines and absorb revenue volatility without urgent refinancing. A conservative capital structure preserves strategic optionality over the medium term.
Sustained Revenue GrowthMulti-year top-line growth with accelerating annual revenue indicates product traction and effective commercialization. Persistent revenue expansion supports scalable margins, funds further development and licensing activities, and underpins sustainable organic cash generation if operating performance stabilizes.
Diversified Partner Revenue StreamsOut-licensing and collaboration revenues create non-linear upside and reduce single-product or single-market exposure. Milestones and royalties can finance development, lower capital intensity, and align incentives with larger partners, strengthening long-term commercial reach and risk-sharing.
Bears Say
Weak Cash GenerationOperating and free cash flow volatility, with multiple negative years, signals poor cash conversion and sizable working-capital swings. This limits the firm's ability to self-fund R&D, capital expenditures or payouts, increasing reliance on reserves, partners or external financing for strategic initiatives.
Operating Profit DeteriorationAn operating-profit decline to negative despite revenue gains suggests margin pressure or rising operating costs. Persistent operating losses weaken earnings quality, strain internal funding for innovation and commercialization, and raise the firm's dependence on non-operating items or partner payments to sustain reported profitability.
Domestic Market ConcentrationHeavy reliance on the Japanese market concentrates regulatory, pricing and demographic risk. Limited geographic diversification can cap addressable market growth and leave revenues sensitive to domestic reimbursement changes or competitive dynamics, constraining longer-term scaling absent successful international partnerships.
Kissei Pharmaceutical Co News
4547 FAQ
What was Kissei Pharmaceutical Co Ltd’s price range in the past 12 months?
Kissei Pharmaceutical Co Ltd lowest stock price was ¥3500.00 and its highest was ¥5040.00 in the past 12 months.
What is Kissei Pharmaceutical Co Ltd’s market cap?
Kissei Pharmaceutical Co Ltd’s market cap is ¥153.38B.
When is Kissei Pharmaceutical Co Ltd’s upcoming earnings report date?
Kissei Pharmaceutical Co Ltd’s upcoming earnings report date is Aug 03, 2026 which is in 59 days.
How were Kissei Pharmaceutical Co Ltd’s earnings last quarter?
Kissei Pharmaceutical Co Ltd released its earnings results on May 11, 2026. The company reported ¥66.77 earnings per share for the quarter, missing the consensus estimate of ¥81.931 by -¥15.161.
Is Kissei Pharmaceutical Co Ltd overvalued?
According to Wall Street analysts Kissei Pharmaceutical Co Ltd’s price is currently Undervalued.
Does Kissei Pharmaceutical Co Ltd pay dividends?
Kissei Pharmaceutical Co Ltd pays a Semiannually dividend of ¥60 which represents an annual dividend yield of 2.48%. See more information on Kissei Pharmaceutical Co Ltd dividends here
What is Kissei Pharmaceutical Co Ltd’s EPS estimate?
Kissei Pharmaceutical Co Ltd’s EPS estimate is 55.99.
How many shares outstanding does Kissei Pharmaceutical Co Ltd have?
Kissei Pharmaceutical Co Ltd has 46,541,985 shares outstanding.
What happened to Kissei Pharmaceutical Co Ltd’s price movement after its last earnings report?
Kissei Pharmaceutical Co Ltd reported an EPS of ¥66.77 in its last earnings report, missing expectations of ¥81.931. Following the earnings report the stock price went up 2.059%.
Which hedge fund is a major shareholder of Kissei Pharmaceutical Co Ltd?
Currently, no hedge funds are holding shares in JP:4547
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Kissei Pharmaceutical Co Ltd
Kissei Pharmaceutical Co., Ltd. engages in the research, development, manufacture, and sale of pharmaceutical products primarily in Japan. It offers Urief and Urief OD tablets for the treatment of dysuria; Glufast, Glubes, and Marizev tablets for type 2 diabetes; Darbepoetin Alfa BS and Epoetin Alfa BS injections for the treatment of renal anemia; Beova tablets for overactive bladder treatment; P-TOL chewable tablets for treating hyperphosphatemia; and Minirin Melt OD tablets for nocturia due to nocturnal polyuria in males, central diabetes insipidus, and nocturnal enuresis resulted from decrease of urine osmolality. The company's products in pipeline include KPS-0373 that has completed Phase III clinical trial to treat spinocerebellar ataxia; CCX168, which has completed Phase III clinical trial for the treatment of microscopic polyangiitis and granulomatosis with polyangiitis; AJM300, which is in Phase III clinical trial to treat ulcerative colitis; R788 that is in Phase III clinical trial to treat chronic idiopathic thrombocytopenic purpura; and MR13A9, which is in Phase III clinical trial to treat uremic pruritus in dialysis patients. It is also developing KLH-2109 for treating endometriosis and uterine fibroids; KDT-3594 for the treatment of Parkinson's disease; Silodosin for dysuria associated with benign prostatic hyperplasia; Mitiglinide for type 2 diabetes mellitus; and Bedoradrine for the treatment of acute exacerbation of asthma. In addition, it develops and sells protein controlled and energy supply foods; and purchases and sells related materials, as well as offers system development and information processing, construction contracting, equipment and facility management, and information gathering and development support services. The company was formerly known as Kissei Yakuhin Kogyo Co., Ltd. and changed its name to Kissei Pharmaceutical Co., Ltd. in October 1964. The company was founded in 1946 and is headquartered in Matsumoto, Japan.
4547 Stock 12 Month Forecast
Average Price Target
¥5,200.00
▲(12.80% Upside)
Technical Analysis
Kaken Pharmaceutical Co
―
Towa Pharmaceutical Co
―
Mochida Pharmaceutical Co., Ltd.
―
KYORIN Pharmaceutical Co.,Ltd.
―
SAWAI GROUP HOLDINGS Co., Ltd.
―
Options Prices
Currently, No data available
---